harlem.
Everyone has their own opinions on this topic. I find the Rabin statement below in line with my thoughts. You could see a "player" get involved with dollars or options to pursue if positive results continue. So many avenues of possibles.
An example:
Oxford BioMedica will receive committed funding of up to US$24 million over the initial phase of development. Oxford BioMedica granted sanofi-aventis a license to develop the products and an option for further development, manufacture and commercialisation on a worldwide basis.
(Rabin from CC)
"I just returned from Europe where we had some great meetings. As far as the RPE program goes, it would be highly premature to seek partners early in the phase 1 study as we are hopeful that even though we are dealing with late stage patients, we will soon have data on retinal engraftment of our cells, and thier impact on photorecptor function. If we see no safety issues, and are able to detect some engraftment of our cells to the photoreceptor / Bruch's membrane, we will obviously be dealing from a much stronger valuation and negotiating position. It is quite possible that within about 12 weeks of commencement of the trials, we may have a pretty interesting set of data to evaluate and discuss, covering an early look at a total of 6 patients between the two trials."
News 
Market Data 
Discover 
AI
